The Centers for Medicare & Medicaid Services (CMS) annually releases a memorandum that sets the stage for the healthcare industry by establishing the maximum Fair Market Value (FMV) for Agent […]
The Centers for Medicare & Medicaid Services (CMS) revealed on Thursday, August 31st 2023, that the initial group of ten Medicare Part D medications slated for negotiation under the Inflation Reduction Act (IRA) has been identified.
These drugs have been designated based on the outlined criteria within the IRA. This legislation mandates that CMS prioritize drugs with the highest Medicare expenditure and minimal competition, among other […]
(All Times PDT) At This Event:
MWFA training for 2022 opens today with AHIP training now available via their online portal. Find out how to get an AHIP training discount and more.
CMS released information on 2020 premiums and deductibles. For 2020, the Medicare Part B monthly premiums and the annual deductible are higher than the 2019 amounts.
For the 5th year in a row, CMS has raised the maximum rates of Broker and Agent commissions for Medicare Advantage Plans and Prescription Drug Plans. Here are some of the highlights.
The Centers for Medicare & Medicaid Services (CMS) recently released premium and cost-sharing information for Part D plans for the 2020 calendar year. Below are the highlights of a preliminary analysis.
The government currently has no plan for what to do when the money runs short. What are the current possibilities in play? Here is Dr. Steven Weisbart, Chief Economist at the Insurance Information Institute.
“With faster processing times and earlier communication, states now have much greater ability to manage their programs in an effective and predictable manner,” said CMS Administrator Seema Verma. “We want to ease bureaucratic requirements for both states and our own staff so that we can focus those resources on improving health outcomes rather than pushing paperwork.”
Today, the Centers for Medicare & Medicaid Services (CMS) introduced much-needed competition and negotiation into the market for physician-administered and other Part B medications that will result in better deals and lower drug costs for patients.